Advances in Lipid‐Based Codelivery Systems for Cancer and Inflammatory Diseases
Open Access
- 16 December 2022
- journal article
- review article
- Published by Wiley in Advanced Healthcare Materials
- Vol. 12 (7)
Abstract
Combination therapy targeting multiple therapeutic targets is a favorable strategy to achieve better therapeutic outcomes in cancer and inflammatory diseases. Codelivery is a subfield of drug delivery that aims to achieve combined delivery of diverse therapeutic cargoes within the same delivery system, thereby ensuring delivery to the same site and providing an opportunity to tailor the release kinetics as desired. Among the wide range of materials being investigated in the design of codelivery systems, lipids have stood out on account of their low toxicity, biocompatibility, and ease of formulation scale‐up. This review highlights the advances of the last decade in lipid‐based codelivery systems focusing on the codelivery of drug–drug, drug–nucleic acid, nucleic acid–nucleic acid, and protein therapeutic‐based combinations for targeted therapy in cancer and inflammatory diseases.Keywords
Funding Information
- National Institutes of Health (R01 DK120533, R01 CA235863, R01 AA027695)
This publication has 166 references indexed in Scilit:
- Vitamin C-driven epirubicin loading into liposomesInternational Journal of Nanomedicine, 2013
- Nanostructured Lipid Carriers: A potential drug carrier for cancer chemotherapyLipids in Health and Disease, 2012
- Co-delivery of small interfering RNA and plasmid DNA using a polymeric vector incorporating endosomolytic oligomeric sulfonamideBiomaterials, 2011
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerNew England Journal of Medicine, 2011
- Nanoparticles Modified With Tumor-targeting scFv Deliver siRNA and miRNA for Cancer TherapyMolecular Therapy, 2010
- Short Hairpin RNA (shRNA): Design, Delivery, and Assessment of Gene Knockdown2010
- Update of the LIPID MAPS comprehensive classification system for lipidsJournal of Lipid Research, 2009
- Chitosan/siRNA Nanoparticle–mediated TNF-α Knockdown in Peritoneal Macrophages for Anti-inflammatory Treatment in a Murine Arthritis ModelMolecular Therapy, 2009
- Silencing of microRNAs in vivo with ‘antagomirs’Nature, 2005
- Combination therapy to treat moderate to severe psoriasisJournal of the American Academy of Dermatology, 2004